Literature DB >> 8612135

Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice.

A Haziot1, E Ferrero, F Köntgen, N Hijiya, S Yamamoto, J Silver, C L Stewart, S M Goyert.   

Abstract

Endotoxin shock is the result of activation of the immune system by endotoxin/LPS, a component of Gram-negative bacteria. CD14, a GPI-anchored glycoprotein expressed strongly by monocyte/macrophages, is one of several receptors for endotoxin/LPS. The role of CD14 in bacterial-induced and LPS-induced shock was tested in CD14-deficient mice produced by gene targeting in embryonic stem cells. CD14-deficient mice were found to be highly resistant to shock induced by either live Gram-negative bacteria or LPS; however, at very high concentrations of LPS or bacteria, responses through non-CD14 receptors could be detected. Surprisingly, CD14-deficient mice also showed dramatically reduced levels of bacteremia, suggesting an unexpected role for CD14 in the dissemination of Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612135     DOI: 10.1016/s1074-7613(00)80254-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  168 in total

1.  Synthesis and surface expression of CD14 by human endothelial cells.

Authors:  H P Jersmann; C S Hii; G L Hodge; A Ferrante
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 2.  The biology of endotoxin.

Authors:  H Heine; E T Rietschel; A J Ulmer
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

Review 3.  Toll-like receptors: molecular mechanisms of the mammalian immune response.

Authors:  H D Brightbill; R L Modlin
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

4.  Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs.

Authors:  Graciela Andonegui; Claudine S Bonder; Francis Green; Sarah C Mullaly; Lori Zbytnuik; Eko Raharjo; Paul Kubes
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

5.  Glycolipid iGb3 feedback amplifies innate immune responses via CD1d reverse signaling.

Authors:  Xingguang Liu; Peng Zhang; Yunkai Zhang; Zheng Wang; Sheng Xu; Yingke Li; Wanwan Huai; Qingqing Zhou; Xiang Chen; Xi Chen; Nan Li; Peng Wang; Yunsen Li; Xuetao Cao
Journal:  Cell Res       Date:  2018-12-04       Impact factor: 25.617

6.  Involvement of diacylglycerol production in activation of nuclear factor kappaB by a CD14-mediated lipopolysaccharide stimulus.

Authors:  H Yamamoto; K Hanada; M Nishijima
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

7.  Lipopolysaccharide-binding protein- and CD14-dependent activation of mitogen-activated protein kinase p38 by lipopolysaccharide in human neutrophils is associated with priming of respiratory burst.

Authors:  Sen Rong Yan; Walla Al-Hertani; David Byers; Robert Bortolussi
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

8.  Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance.

Authors:  John K Hermann; Madhumitha Ravikumar; Andrew J Shoffstall; Evon S Ereifej; Kyle M Kovach; Jeremy Chang; Arielle Soffer; Chun Wong; Vishnupriya Srivastava; Patrick Smith; Grace Protasiewicz; Jingle Jiang; Stephen M Selkirk; Robert H Miller; Steven Sidik; Nicholas P Ziats; Dawn M Taylor; Jeffrey R Capadona
Journal:  J Neural Eng       Date:  2018-04       Impact factor: 5.379

9.  p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation.

Authors:  Katrin Ramsauer; Iwona Sadzak; Almudena Porras; Andreas Pilz; Angel R Nebreda; Thomas Decker; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

10.  Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.